Updated statistics with estimated new cases and deaths for 2018 (cited American Cancer Society as reference 1).
Revised text to state that although the protocols differed considerably among countries, generally the men were randomly assigned to either a group that offered prostate-specific antigen screening at an average of once every 4 years or to a control group that did not receive screening.
Added text to state that randomization was 1:1 in all countries except Finland, in which it was 1:1.5.
Added text to state that important information that was not reported includes the contamination rate in the entire control group. Also added that there was some evidence that the treatment administered to the prostate cancer cases differed by stage and by randomly assigned group, with the screening group more often receiving radical prostatectomy than the control group; however, no analysis of the overall effect of the difference on the mortality outcome has been reported, and longer follow-up and further analysis will be needed to determine the final results of this trial.
ver historia personal en: www.cerasale.com.ar [dado de baja por la Cancillería Argentina por temas políticos, propio de la censura que rige en nuestro medio]//
weblog.maimonides.edu/farmacia/archives/UM_Informe_Autoevaluacion_FyB.pdf - //
weblog.maimonides.edu/farmacia/archives/0216_Admin_FarmEcon.pdf - //
www.proz.com/kudoz/english_to_spanish/art_literary/523942-key_factors.html - 65k - // www.llave.connmed.com.ar/portalnoticias_vernoticia.php?codigonoticia=17715 // www.frusculleda.com.ar/homepage/espanol/activities_teaching.htm // http://www.on24.com.ar/nota.aspx?idNot=36331 ||